NEW YORK (GenomeWeb) – After several extensions, Abbott completed its tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at $402 per share.

The offer was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday. The offer expired at 11:59 p.m. the same day.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.